DuoGenic StemCells (ROCO:7607) Other Financing: NT$-10.90 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7607 DuoGenic StemCells Corp ROCO:7607
25 GF Score
Price NT$13.00
GF Value NT$51.22
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is DuoGenic StemCells Other Financing?

DuoGenic StemCells ROCO:7607 -0.76% 25 Other Financing is NT$-10.90 Mil as of Dec. 2025. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review.

DuoGenic StemCells's Other Financing for the six months ended in Dec. 2025 was NT$-10.42 Mil.

DuoGenic StemCells's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-10.90 Mil.

DuoGenic StemCells Other Financing Historical Data

* Premium members only.

The historical data trend for DuoGenic StemCells's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells Other Financing Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
-0.05 -0.07 -0.16 -0.56 -0.90

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only -0.11 -0.11 29.56 -0.48 -10.42
ROCO:7607
25GF Score
DuoGenic StemCells Corp ROCO:7607
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DuoGenic StemCells Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-10.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$-10.90 Mil mean?
DuoGenic StemCells (ROCO:7607) has a Other Financing of NT$-10.90 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for DuoGenic StemCells and its competitors.
Is DuoGenic StemCells' Other Financing too high?
DuoGenic StemCells' current Other Financing is NT$-10.90 Mil. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Other Financing compare to VRTX and REGN?
DuoGenic StemCells' Other Financing of NT$-10.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for DuoGenic StemCells and its competitors. DuoGenic StemCells's current Other Financing is NT$-10.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Other Financing is NT$-10.90 Mil. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Other Financing is NT$-10.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?

Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued. The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22. GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.

Key valuation signals for ROCO:7607:

  • Other Financing: NT$-10.90 Mil
  • GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
  • GF Score™: 25/100 with 2 warning signs

No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DuoGenic StemCells Business Description

Address Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score

Get the complete analysis for ROCO:7607

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.00
Price
NT$51.22
GF Value